Site Search
Professionals 196 results
Capabilities 53 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Practice Area
Our Patent Litigation Practice is one of the country’s most active and highly regarded. Our seasoned patent litigators bring extensive courtroom experience to every matter we handle. According to Lex Machina, we are among the top three national patent defense firms in the country for number of appearances and cases filed, and we also were the top national defense firm for number of patent trials in the last five years (2018–2022).
Experience 35 results
Experience
|December 11, 2025
Winston Takes the Checkered Flag After “Massive Win” Settlement
Winston squared off in the W.D.N.C. against lawyers for NASCAR in an antitrust lawsuit brought on behalf of racing teams Front Row Motorsports Inc. and 23X1 Racing LLC—the team co-owned by Michael Jordan and driver Denny Hamlin—alleging monopolization of the market for premier stock car racing teams. On December 11, 2025, nine days into trial and the morning after the plaintiffs rested their case, the parties jointly announced a settlement. Jeffrey Kessler, Jeanifer Parsigian, and Danielle Williams were recognized by American Lawyer with its top “Litigator of the Week” honors on December 19, 2025, for this historic settlement.
Experience
|April 23, 2025
Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination
Winston & Strawn represented Voyager Acquisition Corp. in its announced business combination agreement with VERAXA Biotech AG, a biopharmaceutical company developing next-generation antibody-based cancer therapies. The combination will result in VERAXA becoming a publicly traded company on Nasdaq under the ticker symbol “VERX”, with a pre-money equity valuation of $1.3 billion and up to $253 million in cash held in trust by Voyager. The transaction is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals.
Experience
|May 2, 2024
Winston Represented Industrial Opportunity Partners in Recapitalization of Transcendia Holdings
Winston represented its client Industrial Opportunity Partners (IOP), an Evanston, IL-based private equity firm, in a recapitalization transaction adding new capital and debt reduction for Transcendia Holdings, a Franklin Park, IL-based manufacturer and converter of custom engineered materials. The transaction will provide Transcendia with US$114M in new capital, eliminate more than $200M of the Company's debt, and further strengthen Transcendia's competitive position in the market with additional operating resources. Under the terms of the agreement, an investment fund managed by IOP and investment funds managed by Goldman Sachs Asset Management will lead the capital infusion and recapitalization, which has received unanimous support from the Company's existing second lien lenders and is further supported with a new first lien credit facility from General Atlantic Credit's Atlantic Park Fund. As a result of the transaction, IOP will assume majority ownership of Transcendia, while Goldman Sachs Asset Management, its existing equity sponsor, will maintain a significant minority stake.
Insights & News 1,139 results
Benefits Blast
|February 3, 2026
|3 Min Read
Group Health Plans Must Update HIPAA Notices by February 16 to Address New SUD Privacy Rules
Covered entities, including group health plans, must update and distribute their Health Insurance Portability and Accountability Act of 1996 (HIPAA) Notice of Privacy Practices (NPP) by February 16, 2026, to comply with new rules for handling substance use disorder ) records.
Client Alert
|February 3, 2026
|5 Min Read
UK Crypto Regulation Moves Forward: Lending, Staking & DeFi - Key Takeaways from FCA CP25/40
The close of 2025 highlighted the continuing momentum for the digital asset industry, with regulatory developments accelerating rather than slowing. In December, the UK Government and the Financial Conduct Authority (FCA) released a series of draft instruments and consultation papers that are poised to play a significant role in shaping the sector’s future. On 15 December 2025, HM Treasury (HMT) published a revised draft of The Financial Services and Markets Act 2000 (Cryptoassets) Order 2025. This was followed on 16 December 2025 by the FCA’s publication of three consultation papers addressing core elements of the forthcoming cryptoasset regulatory framework: (1) CP25/40 Regulating Cryptoasset Activities, (2) CP25/41 Regulating Cryptoassets: Admissions & Disclosures and Market Abuse Regime for Cryptoassets, and (3) CP25/42 A Prudential Regime for Cryptoasset Firms. Momentum continued into the new year. On 8 January 2026, the FCA provided further detail on its proposed “gateway” the application process through which firms will seek authorisation to carry on newly regulated cryptoasset activities under the UK’s forthcoming regime.
Press Release
|January 30, 2026
|2 Min Read
Winston & Strawn and Taylor Wessing UK Partnerships Resoundingly Approve Combination
Transatlantic powerhouse Winston Taylor expected to launch in May
Other Results 53 results
Law Glossary
Passed in 1998 and implemented in 2000, the Digital Millennium Copyright Act (DMCA) updated U.S. law to meet the requirements of international copyright treaties. The DMCA addresses challenging issues relating to uses of copyrighted material in the digital environment: it limits the liability of online service providers that meet certain conditions, while providing certain procedures for addressing online infringement; it prohibits circumvention of digital technologies that control or limit access to copyrighted works; and it prohibits the removal or modification of certain types of copyright management information contained in protected works. Title II of the DMCA (sometimes also referred to as the Online Copyright Infringement Liability Limitation Act, or OCILLA) is codified at Section 512, Title 17, of the United States Code.
Site Content
Emerging technology is a term generally used to describe a new technology, but it may also refer to the continuing development of an existing technology; it can have slightly different meaning when used in different areas, such as media, business, science, or education. The term commonly refers to technologies that are currently developing, or that are expected to be available within the next five to ten years, and is usually reserved for technologies that are creating, or are expected to create, significant social or economic effects.
Site Content
Form 8-K is a form required to be filed by registrants with the SEC when certain significant or “material” events occur, such as mergers and acquisitions, changes in management, and director resignations. The form generally must be filed with four business days of the event triggering disclosure.